UCB, a biopharmaceutical company, will present results from Phase 3 studies investigating the impact of bimekizumab on pain and health-related quality of life in moderate-to-severe hidradenitis suppurativa at the Symposium on Hidradenitis Suppurativa Advances. The data provide further evidence of bimekizumab’s potential to treat this chronic inflammatory condition. Despite promising results, the drug has not yet been approved by the US Food and Drug Administration.
Top 12 Risk Assessment Tools for Cyber Security Expected to Dominate in 2025
Hey there, Bay Area friends! Let’s raise a virtual toast to another beautiful day in our city by the bay. Ever noticed the rising tide
